Anavex Life Sciences and Partex NV Group announce AI-based strategic partnership to enhance patient experience
US-based clinical-stage biopharmaceutical company Anavex Life Sciences and German digital pharma platform Partex NV Group have announced a strategic partnership to enhance the patient experience and reshape the biopharma business model.
The partnership will see the two companies combine Anavex’s small molecule (SM) precision medicine drug development platform with Partex’s AI-enabled drug development and sales marketing to co-develop a disease-focused Patient App ecosystem. One feature will be information for patients and caregivers about preventative and curative options available in clinics and on the market.
Partex will also implement AI-based ‘Healthcare Sales Marketing’ for Anavex’s late-stage drug pipeline.
Christopher U Missling PhD, president and CEO of Anavex, stated: “As a biopharmaceutical company with a proprietary late stage pipeline for central nervous system (CNS) indications, Anavex brings expertise in precision medicine drug development to the partnership and we are excited to collaborate with Partex and fully leverage AI to expand beyond our R&D into healthcare sales marketing to bring better treatment options to patients in a patient-centric way.”
Gunjan Bhardwaj PhD, CEO of Partex, commented: “We are excited to embark on this impactful journey together with Anavex. We will start by extending our patient ecosystem together. Further, we intend to leverage our Life Sciences Language Processing platform with Generative AI capabilities, which is expected to significantly improve patient outcomes.”
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …
The National Institute for Health and Care Excellence (NICE) has shared draft guidance surrounding nine …